| __timestamp | Dynavax Technologies Corporation | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 1860000 |
| Thursday, January 1, 2015 | 22180000 | 2963000 |
| Friday, January 1, 2016 | 37257000 | 6961000 |
| Sunday, January 1, 2017 | 27367000 | 11779000 |
| Monday, January 1, 2018 | 64770000 | 13697000 |
| Tuesday, January 1, 2019 | 74986000 | 15749000 |
| Wednesday, January 1, 2020 | 79256000 | 18638000 |
| Friday, January 1, 2021 | 100156000 | 27196000 |
| Saturday, January 1, 2022 | 131408000 | 31739000 |
| Sunday, January 1, 2023 | 152946000 | 33491000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Dynavax consistently outspent Protagonist, with its SG&A expenses growing by an impressive 760%, reaching a peak in 2023. In contrast, Protagonist's expenses increased by approximately 1,700%, albeit from a much smaller base, highlighting its rapid expansion phase. Notably, Dynavax's expenses surged significantly in 2021, coinciding with its strategic initiatives in vaccine development. Meanwhile, Protagonist's steady rise reflects its ongoing investment in research and development. This financial snapshot underscores the dynamic nature of biotech firms as they navigate growth and innovation.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing argenx SE and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Dynavax Technologies Corporation Trends and Insights
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Grifols, S.A. vs Dynavax Technologies Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Arrowhead Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?